A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

Summary

This study is a randomized, double-blind, placebo-controlled, multi-center phase II clinical study conducted in China to compare the efficacy and safety of two different dose groups of AK3280 in IPF patients compared to the placebo control group.

Timeline

Start

2022-07

Primary completion

2024-07

Completion

2024-10

Outcome

Met primary endpoint

release “与安慰剂组相比，用力肺活量改善有显著性差异（ p =0.002）。” arkbiosciences.com ↗

Drugs

Indications